Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Применение ранолазина в терапии ишемической болезни сердца - Научно-практический журнал Cardioсоматика Том 5, №3-4 (2014)
Применение ранолазина в терапии ишемической болезни сердца
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Аннотация
В статье приводятся исследования нового антиангинального препарата – ингибитора натриевых каналов ранолазина. Рассматривается антиангинальное, антиишемическое действие препарата. Описано уменьшение приступов стенокардии, повышение толерантности к физической нагрузке и качества жизни больных со стабильной стенокардией на фоне применения ранолазина. Рассматриваются показания, противопоказания, побочные эффекты, а также основные клинические исследования препарата ранолазин у больных с ишемической болезнью сердца.
Ключевые слова: ишемическая болезнь сердца, стенокардия, острый коронарный синдром, антиангинальная терапия, качество жизни, ранолазин, Ранекса®, ингибитор позднего натриевого тока каналов.
Key words: ischemic heart disease, angina, acute coronary syndrome, antianginal therapy, quality of life, ranolazine, Raneksa® inhibitor of late sodium current channels.
Ключевые слова: ишемическая болезнь сердца, стенокардия, острый коронарный синдром, антиангинальная терапия, качество жизни, ранолазин, Ранекса®, ингибитор позднего натриевого тока каналов.
________________________________________________
Key words: ischemic heart disease, angina, acute coronary syndrome, antianginal therapy, quality of life, ranolazine, Raneksa® inhibitor of late sodium current channels.
Полный текст
Список литературы
1. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients with Stable Ischemic Heart Disease. Circulation 2012; 126: 354–471.
2. US Food and Drug Administration. http://www.fda.gov/ohrms/dockets/ac/03/briefing/4012B2_01_Action%20Letter.pdf
3. Aslam S, Gray D. Ranolazine (Ranexa) in the treatment of chronic stable angina. Adv Ther 2010; 27 (4): 193–201.
4. Lee L, Horowitz J, Flenneaux M. Metabolic manipulation in ischaemic heart disease, a novel approach to treatment. Eur Heart J 2004; 25: 634–41.
5. Lopaschuk GD, Kantor PF, Dyck JRB. Optimizing cardiac metabolism: a new reference approach in the management of ischemic heart disease? Medicographia 1999; 21 (2): 109–15.
6. Reffelmann T, Kloner RA. Ranolazine: anti-anginal drug with further therapeutic potential. Expert Review of Cardiovascular Therapy 2010; 8 (3): 319–329.
7. Stone PH. Ranolazine: New Paradigm for Management of Myocardial Ischemia, Myocardial Dysfunction, and Arrhythmias. Cardiology Clinics 2008; 26 (4): 603–14.
8. Pepine CJ, Wolff AA. A controlled trial a novel anti-ischemic agent, ranolazine, in chronic stable angina pectoris that is responsive to conventional antianginal agents. Ranolazine Study Group. Am J Cardiol 1999; 84: 46–50.
9. Rousseau MF, Pouleur H, Cocco G, Wolff AF. Comparative efficacy of ranolazine versus atenolol for chronic angina pectoris. Am J Cardiol 2005; 95: 311–6.
10. Bassand J-P. Clinical implications of inhibitor of the late sodium current: ranolazine. Eur Heart J 2006; 8 (Suppl. A): A14–A19.
11. Chaitman BR, Pepine CJ, Parker JO et al. Combination Assessment of Ranolazine in Stable Angina (CARISA) Investigators. Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial JAMA 2004; 291: 309–16.
12. Chaitman BR, Skettino SL, Parker JO et al for the MARISA Investigators. Anti-ischemic effects and long-term survival during ranolazinemonotherapy in patients with chronic severe angina. J Am CollCardiol 2004; 43: 1375–82.
13. Stone PH, Gratsiansky NA, Blokhin A et al. Antianginal efficacy of ranolazine when added to treatment with amlodipine: The ERICA (Efficacy of Ranolazine in Chronic Angina) trial. J Am Coll Cardiol 2006; 48 (3): 566–75.
14. Arnold SV, Morrow DA, Lei Y et al. Economic impact of angina after an acute coronary syndrome: Insights from the MERLIN-TIMI 36 trial. Circ Cardiovasc Qual Outcomes 2009; 2 (4): 344–53.
15. Melloni C, Newby LK. Metabolic efficiency with ranolazine for less ischemia in non-ST elevation acute coronary syndromes (MERLIN TIMI-36) study. Expert Rev Cardiovasc Ther 2008; 6 (1): 9–16.
16. Morrow DA, Scirica BM, Karwatowska-Prokopczuk E et al. Evaluation of a novel anti-ischemic agent in acute coronary syndromes: Design and rationale for the Metabolic Efficiency with Ranolazine for Less Ischemia in Non-ST-elevation acute coronary syndromes (MERLIN)-TIMI 36 trial. Am Heart J 2006; 151 (6): 1181–9.
17. Wilson SR, Scirica BM, Braunwald E еt al. Efficacy of ranolazine in patients with chronic angina observations from the randomized, double-blind, placebo-controlled MERLIN-TIMI (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST-Segment Elevation Acute Coronary Syndromes) 36 Trial. J Am Coll Cardiol 2009; 53 (17): 1510–6.
18. Deshmukh SH, Patel SR, Pinassi E et al. Ranolazine improves endothelial function in patients with stable coronary artery disease. Coron Artery Dis 2009; 20 (5): 343–7.
19. Тimmis AD, Chaitman BR, Grager M. Effects of ranolazine on exercise tolerance and HbA1c in patients with chronic angina and diabetes. Eur Heart J 2006; 27 (1): 42–8.
2. US Food and Drug Administration. http://www.fda.gov/ohrms/dockets/ac/03/briefing/4012B2_01_Action%20Letter.pdf
3. Aslam S, Gray D. Ranolazine (Ranexa) in the treatment of chronic stable angina. Adv Ther 2010; 27 (4): 193–201.
4. Lee L, Horowitz J, Flenneaux M. Metabolic manipulation in ischaemic heart disease, a novel approach to treatment. Eur Heart J 2004; 25: 634–41.
5. Lopaschuk GD, Kantor PF, Dyck JRB. Optimizing cardiac metabolism: a new reference approach in the management of ischemic heart disease? Medicographia 1999; 21 (2): 109–15.
6. Reffelmann T, Kloner RA. Ranolazine: anti-anginal drug with further therapeutic potential. Expert Review of Cardiovascular Therapy 2010; 8 (3): 319–329.
7. Stone PH. Ranolazine: New Paradigm for Management of Myocardial Ischemia, Myocardial Dysfunction, and Arrhythmias. Cardiology Clinics 2008; 26 (4): 603–14.
8. Pepine CJ, Wolff AA. A controlled trial a novel anti-ischemic agent, ranolazine, in chronic stable angina pectoris that is responsive to conventional antianginal agents. Ranolazine Study Group. Am J Cardiol 1999; 84: 46–50.
9. Rousseau MF, Pouleur H, Cocco G, Wolff AF. Comparative efficacy of ranolazine versus atenolol for chronic angina pectoris. Am J Cardiol 2005; 95: 311–6.
10. Bassand J-P. Clinical implications of inhibitor of the late sodium current: ranolazine. Eur Heart J 2006; 8 (Suppl. A): A14–A19.
11. Chaitman BR, Pepine CJ, Parker JO et al. Combination Assessment of Ranolazine in Stable Angina (CARISA) Investigators. Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial JAMA 2004; 291: 309–16.
12. Chaitman BR, Skettino SL, Parker JO et al for the MARISA Investigators. Anti-ischemic effects and long-term survival during ranolazinemonotherapy in patients with chronic severe angina. J Am CollCardiol 2004; 43: 1375–82.
13. Stone PH, Gratsiansky NA, Blokhin A et al. Antianginal efficacy of ranolazine when added to treatment with amlodipine: The ERICA (Efficacy of Ranolazine in Chronic Angina) trial. J Am Coll Cardiol 2006; 48 (3): 566–75.
14. Arnold SV, Morrow DA, Lei Y et al. Economic impact of angina after an acute coronary syndrome: Insights from the MERLIN-TIMI 36 trial. Circ Cardiovasc Qual Outcomes 2009; 2 (4): 344–53.
15. Melloni C, Newby LK. Metabolic efficiency with ranolazine for less ischemia in non-ST elevation acute coronary syndromes (MERLIN TIMI-36) study. Expert Rev Cardiovasc Ther 2008; 6 (1): 9–16.
16. Morrow DA, Scirica BM, Karwatowska-Prokopczuk E et al. Evaluation of a novel anti-ischemic agent in acute coronary syndromes: Design and rationale for the Metabolic Efficiency with Ranolazine for Less Ischemia in Non-ST-elevation acute coronary syndromes (MERLIN)-TIMI 36 trial. Am Heart J 2006; 151 (6): 1181–9.
17. Wilson SR, Scirica BM, Braunwald E еt al. Efficacy of ranolazine in patients with chronic angina observations from the randomized, double-blind, placebo-controlled MERLIN-TIMI (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST-Segment Elevation Acute Coronary Syndromes) 36 Trial. J Am Coll Cardiol 2009; 53 (17): 1510–6.
18. Deshmukh SH, Patel SR, Pinassi E et al. Ranolazine improves endothelial function in patients with stable coronary artery disease. Coron Artery Dis 2009; 20 (5): 343–7.
19. Тimmis AD, Chaitman BR, Grager M. Effects of ranolazine on exercise tolerance and HbA1c in patients with chronic angina and diabetes. Eur Heart J 2006; 27 (1): 42–8.
2. US Food and Drug Administration. http://www.fda.gov/ohrms/dockets/ac/03/briefing/4012B2_01_Action%20Letter.pdf
3. Aslam S, Gray D. Ranolazine (Ranexa) in the treatment of chronic stable angina. Adv Ther 2010; 27 (4): 193–201.
4. Lee L, Horowitz J, Flenneaux M. Metabolic manipulation in ischaemic heart disease, a novel approach to treatment. Eur Heart J 2004; 25: 634–41.
5. Lopaschuk GD, Kantor PF, Dyck JRB. Optimizing cardiac metabolism: a new reference approach in the management of ischemic heart disease? Medicographia 1999; 21 (2): 109–15.
6. Reffelmann T, Kloner RA. Ranolazine: anti-anginal drug with further therapeutic potential. Expert Review of Cardiovascular Therapy 2010; 8 (3): 319–329.
7. Stone PH. Ranolazine: New Paradigm for Management of Myocardial Ischemia, Myocardial Dysfunction, and Arrhythmias. Cardiology Clinics 2008; 26 (4): 603–14.
8. Pepine CJ, Wolff AA. A controlled trial a novel anti-ischemic agent, ranolazine, in chronic stable angina pectoris that is responsive to conventional antianginal agents. Ranolazine Study Group. Am J Cardiol 1999; 84: 46–50.
9. Rousseau MF, Pouleur H, Cocco G, Wolff AF. Comparative efficacy of ranolazine versus atenolol for chronic angina pectoris. Am J Cardiol 2005; 95: 311–6.
10. Bassand J-P. Clinical implications of inhibitor of the late sodium current: ranolazine. Eur Heart J 2006; 8 (Suppl. A): A14–A19.
11. Chaitman BR, Pepine CJ, Parker JO et al. Combination Assessment of Ranolazine in Stable Angina (CARISA) Investigators. Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial JAMA 2004; 291: 309–16.
12. Chaitman BR, Skettino SL, Parker JO et al for the MARISA Investigators. Anti-ischemic effects and long-term survival during ranolazinemonotherapy in patients with chronic severe angina. J Am CollCardiol 2004; 43: 1375–82.
13. Stone PH, Gratsiansky NA, Blokhin A et al. Antianginal efficacy of ranolazine when added to treatment with amlodipine: The ERICA (Efficacy of Ranolazine in Chronic Angina) trial. J Am Coll Cardiol 2006; 48 (3): 566–75.
14. Arnold SV, Morrow DA, Lei Y et al. Economic impact of angina after an acute coronary syndrome: Insights from the MERLIN-TIMI 36 trial. Circ Cardiovasc Qual Outcomes 2009; 2 (4): 344–53.
15. Melloni C, Newby LK. Metabolic efficiency with ranolazine for less ischemia in non-ST elevation acute coronary syndromes (MERLIN TIMI-36) study. Expert Rev Cardiovasc Ther 2008; 6 (1): 9–16.
16. Morrow DA, Scirica BM, Karwatowska-Prokopczuk E et al. Evaluation of a novel anti-ischemic agent in acute coronary syndromes: Design and rationale for the Metabolic Efficiency with Ranolazine for Less Ischemia in Non-ST-elevation acute coronary syndromes (MERLIN)-TIMI 36 trial. Am Heart J 2006; 151 (6): 1181–9.
17. Wilson SR, Scirica BM, Braunwald E еt al. Efficacy of ranolazine in patients with chronic angina observations from the randomized, double-blind, placebo-controlled MERLIN-TIMI (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST-Segment Elevation Acute Coronary Syndromes) 36 Trial. J Am Coll Cardiol 2009; 53 (17): 1510–6.
18. Deshmukh SH, Patel SR, Pinassi E et al. Ranolazine improves endothelial function in patients with stable coronary artery disease. Coron Artery Dis 2009; 20 (5): 343–7.
19. Тimmis AD, Chaitman BR, Grager M. Effects of ranolazine on exercise tolerance and HbA1c in patients with chronic angina and diabetes. Eur Heart J 2006; 27 (1): 42–8.
________________________________________________
2. US Food and Drug Administration. http://www.fda.gov/ohrms/dockets/ac/03/briefing/4012B2_01_Action%20Letter.pdf
3. Aslam S, Gray D. Ranolazine (Ranexa) in the treatment of chronic stable angina. Adv Ther 2010; 27 (4): 193–201.
4. Lee L, Horowitz J, Flenneaux M. Metabolic manipulation in ischaemic heart disease, a novel approach to treatment. Eur Heart J 2004; 25: 634–41.
5. Lopaschuk GD, Kantor PF, Dyck JRB. Optimizing cardiac metabolism: a new reference approach in the management of ischemic heart disease? Medicographia 1999; 21 (2): 109–15.
6. Reffelmann T, Kloner RA. Ranolazine: anti-anginal drug with further therapeutic potential. Expert Review of Cardiovascular Therapy 2010; 8 (3): 319–329.
7. Stone PH. Ranolazine: New Paradigm for Management of Myocardial Ischemia, Myocardial Dysfunction, and Arrhythmias. Cardiology Clinics 2008; 26 (4): 603–14.
8. Pepine CJ, Wolff AA. A controlled trial a novel anti-ischemic agent, ranolazine, in chronic stable angina pectoris that is responsive to conventional antianginal agents. Ranolazine Study Group. Am J Cardiol 1999; 84: 46–50.
9. Rousseau MF, Pouleur H, Cocco G, Wolff AF. Comparative efficacy of ranolazine versus atenolol for chronic angina pectoris. Am J Cardiol 2005; 95: 311–6.
10. Bassand J-P. Clinical implications of inhibitor of the late sodium current: ranolazine. Eur Heart J 2006; 8 (Suppl. A): A14–A19.
11. Chaitman BR, Pepine CJ, Parker JO et al. Combination Assessment of Ranolazine in Stable Angina (CARISA) Investigators. Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial JAMA 2004; 291: 309–16.
12. Chaitman BR, Skettino SL, Parker JO et al for the MARISA Investigators. Anti-ischemic effects and long-term survival during ranolazinemonotherapy in patients with chronic severe angina. J Am CollCardiol 2004; 43: 1375–82.
13. Stone PH, Gratsiansky NA, Blokhin A et al. Antianginal efficacy of ranolazine when added to treatment with amlodipine: The ERICA (Efficacy of Ranolazine in Chronic Angina) trial. J Am Coll Cardiol 2006; 48 (3): 566–75.
14. Arnold SV, Morrow DA, Lei Y et al. Economic impact of angina after an acute coronary syndrome: Insights from the MERLIN-TIMI 36 trial. Circ Cardiovasc Qual Outcomes 2009; 2 (4): 344–53.
15. Melloni C, Newby LK. Metabolic efficiency with ranolazine for less ischemia in non-ST elevation acute coronary syndromes (MERLIN TIMI-36) study. Expert Rev Cardiovasc Ther 2008; 6 (1): 9–16.
16. Morrow DA, Scirica BM, Karwatowska-Prokopczuk E et al. Evaluation of a novel anti-ischemic agent in acute coronary syndromes: Design and rationale for the Metabolic Efficiency with Ranolazine for Less Ischemia in Non-ST-elevation acute coronary syndromes (MERLIN)-TIMI 36 trial. Am Heart J 2006; 151 (6): 1181–9.
17. Wilson SR, Scirica BM, Braunwald E еt al. Efficacy of ranolazine in patients with chronic angina observations from the randomized, double-blind, placebo-controlled MERLIN-TIMI (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST-Segment Elevation Acute Coronary Syndromes) 36 Trial. J Am Coll Cardiol 2009; 53 (17): 1510–6.
18. Deshmukh SH, Patel SR, Pinassi E et al. Ranolazine improves endothelial function in patients with stable coronary artery disease. Coron Artery Dis 2009; 20 (5): 343–7.
19. Тimmis AD, Chaitman BR, Grager M. Effects of ranolazine on exercise tolerance and HbA1c in patients with chronic angina and diabetes. Eur Heart J 2006; 27 (1): 42–8.
Авторы
В.С.Задионченко1, Г.Г.Шехян1, А.А.Ялымов*1, С.И.Варенцов2
1 Кафедра поликлинической терапии ГБОУ ВПО МГМСУ им. А.И.Евдокимова Минздрава России;
2 ГБУЗ Городская клиническая больница №24 Департамента здравоохранения г. Москвы
*ayalymov@gmail.com
1 Outpatient therapy department, Evdokimov Medical University;
2 City Clinical Hospital №24, Department of Health in Moscow
*ayalymov@gmail.com
1 Кафедра поликлинической терапии ГБОУ ВПО МГМСУ им. А.И.Евдокимова Минздрава России;
2 ГБУЗ Городская клиническая больница №24 Департамента здравоохранения г. Москвы
*ayalymov@gmail.com
________________________________________________
1 Outpatient therapy department, Evdokimov Medical University;
2 City Clinical Hospital №24, Department of Health in Moscow
*ayalymov@gmail.com
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.